Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Clinical Features of Cystic Fibrosis
The clinical characteristics of CF are exhibited predominantly in the lungs and the gastrointestinal system. Progressive lung disease is responsible for most morbidity and mortality in CF. Chronic sinopulmonary infection and complications including bronchiectasis, loss of lung tissue and function and respiratory insufficiency are directly responsible for mortality. The gastrointestinal component of the disease is primarily due to pancreatic insufficiency, which results in steatorrhea, malnutrition, growth retardation, and osteoporosis. The destructive effect of mucus in the pancreas reduces beta cell function, predisposing patients to CF-related diabetes (CFRD).
Keywords: pulmonary | disease | pancreatic | insufficiency | nutritional | deficiency | malnutrition | CF-related diabetes | diabetes | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.